Ultragenyx Pharmaceutical RARE Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Collaboration And Royalty | $481.14M+17.3% | $410M+25.0% | $328M+17.4% | $279.39M+32.5% | |
| Non Cash Royalty | $111.81M+10.7% | $101M+44.3% | $70M+223% | $21.69M+20.8% | |
| Royalty | $304.22M+10.6% | $275M+50.3% | $183M+744% | $21.69M+20.8% | |
| Revenue by Geography | |||||
| Asia Pacific | $17.72M+96.8% | $9M+350% | $2M+72.3% | $1.16M— | |
| EMEA | $107.67M+34.6% | $80M+66.7% | $48M+32.0% | $36.37M— | |
| Latin America | $170.11M+29.9% | $131M+70.1% | $77M+72.2% | $44.71M+89.2% | |
| North America | $377.21M+10.9% | $340M+10.7% | $307M+9.2% | $281.09M-6.6% | |
| Income Tax Paid Foreign After Refund Received by Geography | |||||
| BR | $1M— | —— | —— | —— | |
| MX | $1M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ultragenyx Pharmaceutical break its business down?
- Ultragenyx Pharmaceutical (RARE) reports revenue by product across 3 parts — Collaboration And Royalty, Non Cash Royalty and Royalty. Each is extracted from the segment footnotes and tracked over time.
- Where does Ultragenyx Pharmaceutical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ultragenyx Pharmaceutical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.